Lofexidine

Generic Name: Lofexidine

Brand Names: Lucemyra

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₂Cl_₂N_₂O

CAS Number: 31036-80-3

Unique Ingredient Identifier: UI82K0T627

Background: Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was...

Indication: Lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment. It is the first non-opioid medication for the symptomatic management of opioid discontinuation.
...

Associated Conditions: Abrupt opioid withdrawal

Associated Therapies: -

Clinical Trials

FDA Approves Protega Pharmaceuticals' Roxybond for Severe Pain Management

FDA approves Protega's Roxybond, an abuse-deterrent, immediate-release 10 mg oxycodone for pain management, using SentryBond tech to reduce misuse via intranasal and IV routes. Despite over 2000 in vitro tests suggesting reduced abuse potential, Protega warns of life-threatening respiratory depression and contraindications. Roxybond aims to address the opioid epidemic, with 3-19% of pain medication users developing addiction.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy